Table 2.
Efficacy and safety of molnupiravir, nirmatrelvir and remdesivir
| Characteristics | Molnupiravir | Nirmatrelvir | Remdesivir |
|---|---|---|---|
| Combined recipe | No | Yes | No |
| Dosing regimens | 800 mg/twice/12 h* | 300 mg/twice/day* | 100 mg/day* |
| Administrative route | Oral | Oral | Intravenous |
| Adults; children ages 12 years and older | Yes | ||
| Adults and children (28 days of age) | Yes | ||
| Adults | Yes | ||
| Over placebo in hospitalization/death | 6.77 over 9.72%a | 0.77 over 6.41%b | |
| Days to recovery (Treatment/control) | 0.73/1.10c | ||
| Over placebo in serious adverse events | 7.18 over 11.41%a | 6.68 over 16.14%b | 0.69–0.78c |
*
Fact sheet for healthcare providers: Emergency use of authorization for lagevrio™ (molnupiravir) capsules. Revised EUA Authorized Date: 08/2022; Fact sheet for healthcare providers: Emergency use of authorization for Paxlovid™. Original EUA Authorized Date: 12/2021. Veklury FDA Approval History (https://www.drugs.com/history/veklury.html).
a
[73];
b
[74];